Cevimeline, a parasympathomimetic and muscarinic agonist, affects M1 and M3 receptors. Cevimeline has been shown to treat dry mouth and Sj gren's syndrome. It is also used to reduce Xerostomia symptoms and increase salivary flow in head and neck cancer survivors after radiotherapy.

107233-08-9

C10H17NOS

199.31

FKS 508;HSDB 7286;西维美林;AF-102B;SNI 2011;Cevimeline

DMSO:Soluble
Powder: -20°C for 3 years
In solvent: -80°C for 2 years